A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society

Lothar Bergmann(Universität Ulm), Thomas Gauler, Jochen Greiner(Universität Ulm), Arndt Hartmann(Universitätsklinikum Erlangen), Anne Flörcken(Humboldt-Universität zu Berlin), Jan Schleicher(Klinikum Stuttgart), Luise Maute(Goethe University Frankfurt), Theodor Klotz, Viktor Grünwald(Deutsche Schmerzgesellschaft), Steffen Weikert(St. Hedwig-Krankenhaus), Marc‐Oliver Grimm(Klinik und Poliklinik für Urologie)
Oncology Research and Treatment
January 1, 2020
10.1159/000508450
Cited by 35

Related Papers

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
|European Urology|2008|617
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
|The Lancet Oncology|2017|431
Dose-Response Association of CD8<sup>+</sup> Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
|JAMA Oncology|2017|409